Phase 3 (Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Inebilizumab-cdon (Anti-CD19 mAb) in Myasthenia Gravis
ClinicalTrials.gov (NCT04524273): Myasthenia Gravis Inebilizumab Trial (MINT)
WHAT IS THE CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Updated by HC
VIE, Inebilizumab-cdon (Anti-CD19 mAb), Myasthenia Gravis, neuromuscular disorder that causes weakness in the skeletal muscles,
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post